vidarabine has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 99 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (12.12) | 18.2507 |
| 2000's | 37 (37.37) | 29.6817 |
| 2010's | 38 (38.38) | 24.3611 |
| 2020's | 12 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A | 1 |
| Admiraal, R; Bierings, M; Blok, H; Calkoen, FG; De Koning, C; Dekker, L; Hoogerbrugge, P; Huitema, ADR; Jiang, Y; Lindemans, CA; Nierkens, S; Nijstad, AL; Pieters, R; Spoon, M; Van Der Elst, KCM; Van Der Vlugt, M; Van Tinteren, H; Veldkamp, SR; Visscher, H; Vormoor, B; Vormoor, HJ | 1 |
| Arora, S; Di Stasi, A; Jamy, O; Meredith, R; Minagawa, K; Mineishi, S; Saad, A; Salzman, D | 1 |
| Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z | 1 |
| Chan, WYK; Cheuk, DKL; Cheung, C; Ha, SY; Kan, EYL; Lee, PPW; Leung, W; Shelia, WSN; Tso, WWY; Yeung, WL | 1 |
| Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 1 |
| Jayakumar, I; Patel, S; Raj, R; Ramakrishnan, B; Ramanan, KM; Ravichandran, N; Swaminathan, VV; Uppuluri, R | 1 |
| Al Malki, MM; Aldoss, I; Ali, H; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; Pullarkat, V; Salhotra, A; Sandhu, K; Smith, E; Snyder, D; Stein, A; Tsai, NC | 1 |
| Atsuta, Y; Fukuda, T; Imahashi, N; Inamoto, Y; Ishikawa, J; Kako, S; Kanda, J; Kimura, T; Kobayashi, H; Kondo, E; Kozai, Y; Matsuoka, KI; Sakai, H; Tanaka, M; Terakura, S; Uchida, N | 1 |
| Choi, Y; Do, YR; Jung, SH; Kim, DS; Koh, Y; Lee, JH; Lee, S; Lee, SS; Lee, WS; Moon, JH; Mun, YC; Park, HS; Park, Y; Yang, DH; Yhim, HY; Yi, JH | 1 |
| Bar, M; Bezerra, ED; Cassaday, RD; Chapuis, AG; Chou, CK; Cowan, AJ; Fiorenza, S; Gauthier, J; Green, DJ; Hawkins, RM; Hirayama, AV; Jamieson, AW; Kiem, HP; Kimble, EL; Maloney, DG; Milano, F; Pender, BS; Phi, TD; Riddell, SR; Shadman, M; Sheih, A; Steinmetz, RN; Till, BG; Turtle, CJ; Vakil, A | 1 |
| Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A | 1 |
| Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S | 1 |
| Arasteh, O; Hadjibabaie, M; Taghvaye Masoumi, H; Zarif-Yeganeh, M | 1 |
| Aoki, J; Atsuta, Y; Eto, T; Fukuda, T; Ichinohe, T; Ishiyama, K; Iwato, K; Kahata, K; Kako, S; Kanamori, H; Kanda, Y; Kawamura, K; Kondo, T; Mizuta, S; Ozawa, Y; Sawa, M; Uchida, N; Yano, S | 1 |
| Cao, Q; Dusenbery, KE; Gao, RW; Smith, AR; Yuan, J | 1 |
| Abou Mourad, Y; Abuhaleeqa, M; Daly, A; Nitta, J; Paulson, K; Seftel, MD; Speziali, C | 1 |
| Aymerich, M; Bataller, A; Camós, M; Colomer, D; Díaz-Beyá, M; Esteve, J; Garrote, M; López-Guerra, M; Oliver-Caldés, A; Vega-García, N | 1 |
| Tian, C; Yu, Y; Zhang, Y | 1 |
| Abdalla, K; Abrar, MB; AlAzmi, AA; Elimam, N; Jastaniah, W; Mustafa, O | 1 |
| Chung, Y; Han, B; Kim, HY; Kim, M; Lee, J; Lee, YK; Park, JY | 1 |
| Cao, J; Chen, W; Cheng, H; Jing, G; Li, H; Qi, K; Qiao, J; Shi, M; Wang, G; Wu, Q; Xu, K; Zeng, L; Zhao, J; Zheng, J | 1 |
| Anasetti, C; Ayala, E; Betts, B; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kunter, G; Locke, F; Nieder, M; Nishihori, T; Ochoa-Bayona, JL; Perez, L; Perkins, JB; Pidala, J; Tomblyn, M | 1 |
| Eto, T; Fukuda, T; Ikegame, K; Imai, K; Kako, S; Kanamori, H; Kato, H; Minagawa, K; Mizuta, S; Morishima, Y; Nagamura-Inoue, T; Nakamae, H; Nishiwaki, S; Sakamaki, H; Shigematsu, A; Suzuki, R; Tanaka, J; Tanaka, M; Yujiri, T | 1 |
| Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N | 1 |
| Ball, LM; Bredius, RG; Hissink Muller, P; Jol-van der Zijde, EC; Lankester, AC; Vermont, CL; Vossen, AC | 1 |
| Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Cruciani, F; De Astis, E; Di Grazia, C; Galaverna, F; Ghiggi, C; Ghiso, A; Gobbi, M; Guolo, F; Lemoli, RM; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G; Raiola, AM; Varaldo, R | 1 |
| Ding, K; Geng, L; Liu, H; Liu, X; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zheng, C; Zhu, X | 1 |
| Ahn, HS; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Kim, S; Lee, JW; Lee, SH; Park, JD; Park, KD; Shin, HY; Song, SH; Yu, KS | 1 |
| Fujisawa, S; Ishibashi, D; Ishigatsubo, Y; Kawasaki, R; Koharazawa, H; Matsumoto, K; Nakajima, Y; Tachibana, T; Tanaka, M; Yamamoto, E | 1 |
| Goto, H; Goto, S; Yokosuka, T | 1 |
| Ding, K; Geng, L; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zhang, L; Zhang, X; Zheng, C; Zhu, X | 1 |
| Hey, SP; Kesselheim, AS | 1 |
| Hawkes, N | 1 |
| Chen, ZC; Li, QB; Li, WM; Xia, LH; You, Y; Zhou, H; Zou, P | 1 |
| Hong, M; Li, JY; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R | 1 |
| Bruns, I; Czibere, A; Fenk, R; Gräf, T; Haas, R; Kobbe, G; Schroeder, T; Zohren, F | 1 |
| Cho, BS; Cho, SG; Chung, NG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Eyzaguirre-Zapata, R; Gómez-Almaguer, D; González-Carrillo, ML; Gutiérrez-Aguirre, CH; Gutiérrez-Riveroll, KI; Priesca-Marin, M; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ | 1 |
| Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC | 1 |
| Abad, L; Diaz, MA; Gonzalez-Vicent, M; Perez, A; Ramirez, M; Sevilla, J | 1 |
| Aytac, S; Balci, YI; Cetin, M; Gumruk, F; Gurgey, A; Kuskonmaz, B; Tavil, B; Tuncer, M; Uckan, D; Unal, S; Yetgin, S | 1 |
| Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE | 1 |
| Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R | 1 |
| Alsina, M; Anasetti, C; Ayala, E; Di Nicola, M; Fernandez, H; Field, T; Janssen, W; Kharfan-Dabaja, MA; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Santarone, S | 1 |
| Chen, S; Du, X; Li, Y; Liu, Q; Wu, J; Wu, X; Yang, L; Zhu, K | 1 |
| Bae, SH; Choi, SJ; Hyun, MS; Jeon, M; Joo, YD; Kang, MJ; Kang, YA; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Lee, YS; Park, JH; Ryoo, HM; Seol, M; Yun, SC | 1 |
| Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ | 1 |
| Barisone, E; Berger, M; Fagioli, F; Galletto, C; Manicone, R; Masetti, R; Pession, A; Quarello, P; Rivetti, E | 1 |
| Chae, YS; Choi, JY; Kang, BW; Kim, JG; Kim, YK; Lee, SJ; Lee, YJ; Moon, JH; Seo, JW; Shin, HC; Sohn, SK; Suh, JS | 1 |
| Almazi, JG; Best, OG; Christopherson, RI; Crossett, B; Mactier, S; Mulligan, SP | 1 |
| Bahlis, N; Brown, C; Chaudhry, A; Daly, A; Duggan, P; Geddes, M; Russell, J; Savoie, ML; Shafey, M; Stewart, D; Storek, J; Turner, AR | 1 |
| Helton, KJ; Patay, Z; Triplett, BM | 1 |
| Duszeńko, E; Haus, O; Kałwak, K; Musiał, J; Ussowicz, M | 1 |
| Cook, G; Craddock, CF; Fielding, AK; Kirkland, KE; Littlewood, TJ; Marks, DI; Medd, PG; Milligan, DW; Pearce, R; Peniket, AJ; Perry, J; Potter, MN; Shaw, BE | 1 |
| Batár, P; Kiss, A; Rák, K; Rejtó, L; Reményi, G; Telek, B; Udvardy, M | 1 |
| Agura, E; Anasetti, C; Blume, K; Chauncey, T; Hegenbart, U; Heimfeld, S; Maloney, D; Maris, MB; McSweeney, P; Niederwieser, D; Petersdorf, E; Pulsipher, M; Sandmaier, BM; Slattery, J; Storb, R; Storer, B; Stuart, M; Woolfrey, A | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C | 1 |
| Arnold, R; Dörken, B; Heine, F; Le Coutre, P; Massenkeil, G; Nagy, M; Rosen, O | 1 |
| Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ | 1 |
| Abdall, N; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gatto, S; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R; Venturino, C | 1 |
| Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Carluccio, P; Ciuffreda, L; Liso, A; Liso, V; Mestice, A; Pastore, D; Pietrantuono, G; Rizzi, R; Specchia, G | 1 |
| Bao, L; Huang, XJ; Jiang, B; Lu, DP; Lu, J; Lu, XJ; Qiu, JY; Shi, HX; Wang, DB; Wang, FR | 1 |
| Disel, U; Paydas, S; Yavuz, S | 1 |
| Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U | 1 |
| Adamczyk-Cioch, M; Dmoszynska, A; Giebel, S; Holowiecki, J; Jakubas, B; Krawczyk-Kulis, M; Lewandowski, K; Nowak, K; Palynyczko, G; Skotnicki, A | 1 |
| Fujii, H; Goto, H; Ikuta, K; Isaki, S; Kajiwara, R; Kuroki, F; Takahashi, H; Yanagimachi, M; Yokota, S | 1 |
| Bertz, H; Bley, TA; Feuerhake, F; Finke, J; Mielke, S; Potthoff, K; Windfuhr, M | 1 |
| Chuhjo, T; Kondo, Y; Kotani, T; Nakao, S; Ohtake, S; Okumura, H; Ozaki, J; Sugimori, C; Sugimori, N; Takami, A; Ueda, M; Yamaguchi, M; Yamazaki, H | 1 |
| Allwinn, R; Beske, F; Klingebiel, T; Kriener, S; Lehrnbecher, T; Modrow, S; Schmidt, H; Schwabe, D; Sörensen, J | 1 |
| Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR | 1 |
| Giles, FJ; Gojo, I; Greer, J; Johnson, B; Karp, JE; Low, J; Morris, L; Sznol, M; Thein, M | 1 |
| Gesundheit, B; Resnick, IB | 1 |
| Bifulco, C; Parnes, A; Vanasse, GJ | 1 |
| Díaz, MA; González-Vicent, M; Madero, L; Pérez, A; Ramirez, M; Sevilla, J | 1 |
| Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A | 1 |
| Curbo, S; Karlsson, A | 1 |
| Hirokawa, M; Kitabayashi, A; Kuroki, J; Miura, AB; Niitsu, H; Nishinari, T | 1 |
| Beran, M; Estey, E; Gandhi, V; Kantarjian, H; Keating, M; O'Brien, S; Plunkett, W; Rios, MB; Suki, S | 1 |
| Cortes-Franco, J; Estey, E; Kornblau, SM | 1 |
| Carrara, P; Cenacchi, A; Clavio, M; Gobbi, M; Manfroi, S; Ottaviani, E; Tosi, P; Tura, S; Visani, G; Zinzani, PL | 1 |
| Cohen, JD; Katz, TB; Marcel, PD; Strock, DJ; Teik, JE | 1 |
| Centurioni, R; Leoni, P; Montillo, M; Tedeschi, A | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Avramis, VI; Kowck, R; Krailo, MD; Liu-Mares, W; Ramilo-Torno, LV; Reaman, GH; Sato, JK; Sharpe, A; Wiersma, S | 1 |
| Deane, M; Foroni, L; Galactowicz, G; Hoffbrand, AV; Koh, M; Lawler, M; Prentice, HG; Secker-Walker, L | 1 |
| Hann, IM; McCarthy, AJ; Oakhill, A; Pitcher, LA | 1 |
| Byrne, JL; Dasgupta, E; Forman, K; Haynes, AP; Mitchell, D; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Molinari, A; Poletti, G; Poletti, V; Salvucci, M; Zaccaria, A; Zanchini, R; Zuffa, E | 1 |
| Ayres, M; Du, M; Gandhi, V; Hodge, JP; Keating, MJ; O'Brien, S; Plunkett, W; Ramakrishna, P; Rodriguez, CO; Rosner, GL; Weller, S | 1 |
| Braess, J; Büchner, T; Hiddemann, W; Kern, W; Ohnesorge, J; Schleyer, E; Unterhalt, M; Wittmer, E; Wörmann, B | 1 |
| Lim, LC; Ng, HJ | 1 |
| Craddock, C; Garg, M; Lawler, M; Pawson, R; Potter, MN; Prentice, HG; Rassam, S; Rezvani, K; Theocharous, P; Yin, JA | 1 |
| Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R | 1 |
| Blatt, J; Hammond, GD; Krailo, MD; Miser, JS; Reaman, GH; Roloff, J | 1 |
2 review(s) available for vidarabine and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
[Experience with fludarabine treatment and review of the literature].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Remission Induction; Treatment Outcome; Vidarabine | 2002 |
Nelarabine: a new purine analog in the treatment of hematologic malignancies.
Topics: Arabinonucleosides; Clinical Trials as Topic; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Leukemia-Lymphoma, Adult T-Cell; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Vidarabine | 2006 |
33 trial(s) available for vidarabine and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2022 |
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Topics: Adult; Aged; Antigens, CD19; Cell Proliferation; Cyclophosphamide; Cytokine Release Syndrome; Female; Humans; Immunotherapy, Adoptive; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Progression-Free Survival; T-Lymphocytes; Treatment Outcome; Vidarabine | 2021 |
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation | 2021 |
Augmenting Total Body Irradiation with a Cranial Boost before Stem Cell Transplantation Protects Against Post-Transplant Central Nervous System Relapse in Acute Lymphoblastic Leukemia.
Topics: Adolescent; Adult; Allografts; Central Nervous System Neoplasms; Child; Child, Preschool; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Trial of novel leukaemia drug is stopped for second time after two more deaths.
Topics: Antineoplastic Agents; Brain Edema; Early Termination of Clinical Trials; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; United States; United States Food and Drug Administration; Vidarabine | 2016 |
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2009 |
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine | 2010 |
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Medical Records; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Models, Statistical; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sex Factors; Societies, Medical; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine | 2013 |
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Antigens Class I; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Acute; Lymphocyte Transfusion; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Tissue Donors; Vidarabine; Whole-Body Irradiation | 2003 |
[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 2003 |
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine | 2004 |
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Topotecan; Vidarabine | 2004 |
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Liposomes; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mitoxantrone; Poland; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Sepsis; Time Factors; Transplantation, Homologous; Vidarabine | 2006 |
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Recurrence; Thiosemicarbazones; Treatment Outcome; Vidarabine | 2008 |
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Vidarabine | 2008 |
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 1993 |
FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Conjunctivitis; Cytarabine; Disease-Free Survival; Female; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Ophthalmic Solutions; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vidarabine | 1996 |
Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1998 |
FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 1999 |
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arabinonucleotides; Biomarkers; Female; Guanosine Triphosphate; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Prolymphocytic; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Treatment Outcome; Vidarabine | 2001 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Humans; Leukemia; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2001 |
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Lack of significant activity of 2'-deoxycoformycin alone or in combination with adenine arabinoside in relapsed childhood acute lymphoblastic leukemia. A randomized phase II trial from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Drug Synergism; Humans; Immunophenotyping; Pentostatin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 1992 |
64 other study(ies) available for vidarabine and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2022 |
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Topics: Antigens, CD19; Child; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Retrospective Studies; Vidarabine; Young Adult | 2022 |
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2023 |
Haploidentical Transplant Achieves Long-Term Remission in Relapsed Refractory Leukemia With Fludarabine-Induced Neurotoxicity Complication.
Topics: Child; Hematopoietic Stem Cell Transplantation; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Transplants; Vidarabine | 2023 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2019 |
FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Child, Preschool; Cytarabine; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Vidarabine | 2021 |
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Topics: Aged; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2020 |
Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies.
Topics: Busulfan; Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2020 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Exacerbation of allopurinol-induced drug reaction with eosinophilia and systemic symptoms by teicoplanin: A case report.
Topics: Allopurinol; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Hypersensitivity Syndrome; Female; Gout Suppressants; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Teicoplanin; Vidarabine | 2017 |
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2017 |
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2019 |
Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sorafenib; Treatment Outcome; Vidarabine | 2019 |
Waldenström macroglobulinaemia terminating in acute lymphoblastic leukaemia after treatment with fludarabine.
Topics: Aged; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine; Waldenstrom Macroglobulinemia | 2019 |
FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Vidarabine | 2019 |
First Report of a Patient With Natural Killer-Lymphoblastic Leukemia/Lymphoma in Korea.
Topics: Antineoplastic Agents; Bone Marrow Cells; Clopidogrel; Drug Therapy, Combination; Female; Humans; Killer Cells, Natural; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Republic of Korea; Tomography, X-Ray Computed; Vidarabine | 2019 |
Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.
Topics: Aged; Antigens, CD19; B-Lymphocytes; Cell Separation; Cyclophosphamide; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Kinetics; Leukemia, B-Cell; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell; Remission Induction; T-Lymphocytes; Vidarabine | 2019 |
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Topics: Age Factors; Aged; B-Lymphocytes; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2013 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
Topics: Adolescent; Antineoplastic Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Herpesvirus 3, Human; Humans; Immunity, Cellular; Immunosuppression Therapy; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; T-Lymphocytes; Vidarabine; Virus Activation; Young Adult | 2014 |
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2014 |
A myeloablative conditioning regimen with fludarabine demonstrates good results in UCBT for 30 pediatric patients with hematologic malignancies, especially acute lymphoblastic leukemia.
Topics: Adolescent; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Humans; Male; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Transplantation Conditioning; Vidarabine | 2014 |
Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Topics: Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Injections, Intravenous; Male; Myeloablative Agonists; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult | 2015 |
Successful Engraftment and Durable Graft-versus-host Disease Control with Haploidentical Peripheral Blood and a Short-term Conditioning Regimen for Primary Graft Failure.
Topics: Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Topics: Adenine Nucleotides; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Child; Cladribine; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2016 |
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Mycophenolic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
The FDA, Juno Therapeutics, and the ethical imperative of transparency.
Topics: Brain Edema; Clinical Trials, Phase II as Topic; Disclosure; Drug Industry; Drugs, Investigational; Humans; Immunotherapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Safety-Based Drug Withdrawals; United States; United States Food and Drug Administration; Vidarabine | 2016 |
Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine | 2008 |
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting.
Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Donors; Busulfan; Catheter Ablation; Cost-Benefit Analysis; Cyclophosphamide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mexico; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
Topics: Adolescent; Antigens, CD19; Antineoplastic Agents; CD3 Complex; Child; Child, Preschool; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2010 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Flow Cytometry; Gene Rearrangement, T-Lymphocyte; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Myeloid; Leukocytes, Mononuclear; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Thymus Gland; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Salvage Therapy; Survival Rate; Vidarabine | 2012 |
Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.
Topics: Adolescent; Adult; Busulfan; Chi-Square Distribution; Disease-Free Survival; Drug Therapy, Combination; Feasibility Studies; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cytosol; DNA-Binding Proteins; Humans; Membrane Proteins; Nuclear Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2012 |
Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities.
Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Comorbidity; Disease-Free Survival; Humans; Incidence; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2012 |
Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation.
Topics: Adolescent; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukoencephalopathies; Male; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine | 2013 |
Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia; Busulfan; Child, Preschool; Humans; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Siblings; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine | 2013 |
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infection Control; Infections; Leukemia, Myeloid; Male; Middle Aged; Mycophenolic Acid; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine | 2005 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukocyte Count; Liver; Male; Middle Aged; Mucositis; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Teniposide; Treatment Outcome; Vidarabine | 2005 |
Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Liver Diseases; Male; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2006 |
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Drug Evaluation; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Topotecan; Treatment Outcome; Vidarabine; Vinblastine | 2005 |
[Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Cyclosporine; Graft vs Host Disease; Humans; Infant; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tissue Donors; Transplantation Conditioning; Vidarabine | 2006 |
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclosporine; Demyelinating Diseases; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Stem Cell Transplantation; Vidarabine | 2007 |
Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Blast Crisis; Chimera; Cord Blood Stem Cell Transplantation; Disease Progression; Fatal Outcome; Female; Graft Rejection; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Immunity, Maternally-Acquired; Isoantigens; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine | 2007 |
Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Combined Modality Therapy; Erythema Infectiosum; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Parvovirus B19, Human; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiography, Thoracic; Recurrence; Thiotepa; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Regurgitation of esophageal mucosa.
Topics: Adult; Busulfan; Esophagitis; Esophagus; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucositis; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine; Vomiting | 2007 |
A novel regimen incorporating the concomitant administration of fludarabine and alemtuzumab for the treatment of refractory adult acute lymphoblastic leukaemia: a report of three cases.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Female; Humans; Male; Middle Aged; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Vidarabine | 2007 |
Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients.
Topics: Adolescent; Antigens, CD34; Antineoplastic Agents; CD3 Complex; Child; Child, Preschool; Disease-Free Survival; Female; Graft vs Leukemia Effect; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Prospective Studies; Recurrence; Stem Cells; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation.
Topics: Adenovirus Infections, Human; Adult; Bone Marrow Transplantation; Cystitis; Hematuria; Humans; Male; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine | 1994 |
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1993 |
Deoxycytidine in human plasma: potential for protecting leukemic cells during chemotherapy.
Topics: Adult; Cladribine; Cytarabine; Deoxycytidine; Deoxycytosine Nucleotides; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Transplantation, Homologous; Treatment Outcome; Vidarabine | 1998 |
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine | 1999 |
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Infant, Newborn; Leukemia; Leukemia, Myeloid, Acute; Lung Diseases; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory Distress Syndrome, Newborn; Staphylococcal Infections; Vidarabine | 2000 |
Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rituximab; Vidarabine; Virus Activation | 2001 |
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Filgrastim; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Reoperation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |